Shares of Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) rose 3.1% during mid-day trading on Tuesday . The company traded as high as C$3.88 and last traded at C$3.76. Approximately 42,504 shares traded hands during trading, an increase of 474% from the average daily volume of 7,410 shares. The stock had previously closed at C$3.65.
Eupraxia Pharmaceuticals Stock Performance
The company’s 50 day moving average is C$3.12 and its 200 day moving average is C$2.92.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc, a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis.
Read More
- Five stocks we like better than Eupraxia Pharmaceuticals
- What is the Nasdaq? Complete Overview with History
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- How to Short Nasdaq: An Easy-to-Follow Guide
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
